Lipella Pharmaceuticals(LIPO)

Focus: Lipella Pharmaceuticals is a public-stage biotech company focused on liposomal drugs and diagnostics, primarily targeting neurology indications with an early-stage pipeline.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Lipella Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Lipella Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$450K

Pipeline & Clinical Trials

Ferumoxytol

IC - Interstitial Cystitis

Phase 1

Clinical Trials (1)

NCT05811377Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay

Phase 1

Help build intelligence for Lipella Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform company with proprietary liposomal drug technology offering ground-floor opportunity to shape drug development strategy
Public company status provides liquidity and institutional credibility despite pre-revenue stage
Focused therapeutic area (neurology, urology) allows for deep specialization and impact on niche patient populations

Watch Out For

Extreme financial burn ($4.6M net loss on $450K revenue in FY2024) with only $3M cash remaining creates existential runway risk
Zero active job postings and minimal disclosure of headcount suggest severely constrained hiring and potential restructuring ahead
No Phase 3 programs, no marketed products, and only 4 total trials in pipeline leave 5+ years minimum to any meaningful revenue inflection

Generated by Claude from Lipella Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

LP-08 80mg

Interstitial Cystitis

Phase 2

Clinical Trials (1)

NCT01393223Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

Phase 2

LP-10

Hemorrhagic Cystitis

Phase 2

Clinical Trials (1)

NCT03129126The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

Phase 2

LP-10

Oral Lichen Planus

Phase 2

Clinical Trials (1)

NCT06233591Evaluating LP-10 in Subjects With OLP

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2024)

Revenue

$450K144%

R&D Spend

$3M(676%)19%

Net Income

-$5M

Cash

$3M

Source: SEC 10-K Filing